🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "major milestone" in the fight against increasingly resistant strains of the bacteria, according to health experts.

A Worldwide Public Health Issue

Gonorrhoea infections are increasing globally, with figures suggesting over 82 million infections each year. Notably increased rates are observed in Africa and countries within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a record high, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary development in the reality of increasing worldwide cases, increasing antimicrobial resistance and the very limited therapeutic options at this time.”

Public health authorities are particularly alarmed about the surge in antibiotic-resistant strains. The global health body has designated it as a "priority pathogen". Recent surveillance found that the effectiveness of standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Treatment Options Secure Authorization

One new antibiotic, also known as Nuzolvence, was approved by the US Food and Drug Administration in December for treating gonorrhoea. This STI can lead to significant complications, including infertility. Experts believe that targeted use of this new drug will help slow the emergence of superbugs.

Gepotidacin, developed by the drugmaker GSK, also received approval in the same week. This medication, which is employed against UTIs, was demonstrated in studies to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

This new treatment emerged from a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to bring it to fruition.

“This authorization marks a significant shift in the treatment of multidrug-resistant gonorrhoea, which up to this point has been outpacing antibiotic development.”

Testing Data and Global Access

As per findings detailed in a major medical journal, zoliflodacin eradicated the vast majority of genital gonorrhoea infections. This establishes an similar efficacy with the current standard treatment, which uses an injection and a pill. The research involved hundreds of participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, the non-profit has the authority to register and commercialise the drug in numerous developing nations.

Medical professionals directly involved have voiced positive views. Access to a single-dose, oral treatment such as this is hailed as a "critical tool" for public health efforts. This is viewed as vital to lessen the impact of the illness for individuals and to halt the transmission of highly drug-resistant gonorrhoea globally.